UnknownPHASE2, PHASE3NCT01301937

Low Antimonial Dosage in American Mucosal Leishmaniasis

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Oswaldo Cruz Foundation
Principal Investigator
Armando O. Schubach, MD, PhD
IPEC/FIOCRUZ
Intervention
Meglumine antimoniate(drug)
Enrollment
76 enrolled
Eligibility
13 years · All sexes
Timeline
2008 – 2021

Study locations (1)

Collaborators

Rio de Janeiro State Research Supporting Foundation (FAPERJ) · Conselho Nacional de Desenvolvimento Científico e Tecnológico

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01301937 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials